Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;52(4):e13710.
doi: 10.1111/eci.13710. Epub 2021 Nov 27.

Oxidized phospholipids and lipoprotein(a): An update

Amalia Despoina Koutsogianni  1 , Evangelos Liberopoulos  1 , Konstantinos Tellis  2 , Alexandros D Tselepis  2
Affiliations
Review

Oxidized phospholipids and lipoprotein(a): An update

Amalia Despoina Koutsogianni et al. Eur J Clin Invest. 2022 Apr.

Abstract

Over the past few years, there has been an undiminished interest in lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs), mainly carried on this lipoprotein. Elevated Lp(a) has been established as an independent causal risk factor for cardiovascular disease. OxPLs play an important role in atherosclerosis. The main questions that remain to be answered, however, is to what extent OxPLs contribute to the atherogenicity of Lp(a), what effect hypolipidaemic medications may have on their levels and the potential clinical benefit of their reduction. This narrative review aimed to summarize currently available data on OxPLs and cardiovascular risk, as well as the effect of established and emerging hypolipidaemic medications on Lp(a)-OxPLs.

Keywords: Lipoprotein(a); antisense oligonucleotides; cardiovascular risk; oxidized phospholipids.

PubMed Disclaimer

References

REFERENCES

    1. Freigang S . The regulation of inflammation by oxidized phospholipids. Eur J Immunol. 2016;46(8):1818-1825. doi:10.1002/EJI.201545676
    1. Friedli O , Freigang S . Cyclopentenone-containing oxidized phospholipids and their isoprostanes as pro-resolving mediators of inflammation. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862(4):382-392. doi:10.1016/J.BBALIP.2016.07.006
    1. Gencer B , Kronenberg F , Stroes E , Mach F . Lipoprotein(a): the revenant. Eur Heart J. 2017;38(20):1553-1560. doi:10.1093/EURHEARTJ/EHX033
    1. Vuorio A , Watts G , Kovanen P . Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a). Eur Heart J. 2017;38(48):3555-3559. doi:10.1093/EURHEARTJ/EHX546
    1. Tsimikas S , Karwatowska-Prokopczuk E , Gouni-Berthold I , et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244-255. doi:10.1056/NEJMOA1905239

LinkOut - more resources